Non-nucleoside structured compounds with antiviral activitydpast 10 years (2010e2020)

被引:8
作者
Denel-Bobrowska, Marta [1 ]
Olejniczak, Agnieszka B. B. [1 ]
机构
[1] Polish Acad Sci, Inst Med Biol, Screening Lab, 106 Lodowa St, PL-93232 Lodz, Poland
关键词
Non-nucleosides; Antiviral agents; Antiviral therapy; Clinical trials; COVID-19; CHRONIC HEPATITIS-C; REVERSE-TRANSCRIPTASE INHIBITOR; IN-VITRO; IMMUNODEFICIENCY-VIRUS; NUCLEOSIDE; DISCOVERY; ANALOG; DRUG; NS5B; RESISTANT;
D O I
10.1016/j.ejmech.2022.114136
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Nucleosides and their derivatives are a well-known and well-described class of compounds with antiviral activity. Currently, in the era of the COVID-19 pandemic, scientists are also looking for compounds not related to nucleosides with antiviral properties. This review aims to provide an overview of selected synthetic antiviral agents not associated to nucleosides developed against human viruses and introduced to preclinical and clinical trials as well as drugs approved for antiviral therapy over the last 10 years. The article describes for the first time the wide classification of such antiviral drugs and drug candidates and briefly summarizes the biological target and clinical applications of the compounds. The described compounds are arranged according to the antiviral mechanism of action. Knowledge of the drug's ac-tivity toward specific molecular targets may be the key to researching new antiviral compounds and repositioning drugs already approved for clinical use. The paper also briefly discusses the future di-rections of antiviral therapy. The described examples of antiviral compounds can be helpful for further drug development. (c) 2022 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:17
相关论文
共 132 条
[1]  
Adebambo K., 2020, COMPUT MOL BIOSCI, V10, P45, DOI [10.4236/cmb.2020.102003, DOI 10.4236/CMB.2020.102003]
[2]   Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment [J].
Agarwal, K. ;
Ahn, S. H. ;
Elkhashab, M. ;
Lau, A. H. ;
Gaggar, A. ;
Bulusu, A. ;
Tian, X. ;
Cathcart, A. L. ;
Woo, J. ;
Subramanian, G. M. ;
Andreone, P. ;
Kim, H. J. ;
Chuang, W. L. ;
Nguyen, M. H. .
JOURNAL OF VIRAL HEPATITIS, 2018, 25 (11) :1331-1340
[3]   A contemporary look at COVID-19 medications: available an potentially effective drugs [J].
Alshaeri, H. K. ;
Natto, Z. S. .
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (17) :9188-9195
[4]  
Alymova I. V., 2005, Current Drug Targets - Infectious Disorders, V5, P401, DOI 10.2174/156800505774912884
[5]   Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management [J].
Anka, Abubakar Umar ;
Tahir, Mohammed Ibrahim ;
Abubakar, Sharafudeen Dahiru ;
Alsabbagh, Mohamed ;
Zian, Zeineb ;
Hamedifar, Haleh ;
Sabzevari, Araz ;
Azizi, Gholamreza .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2021, 93 (04)
[6]   Structural biology in antiviral drug discovery [J].
Bassetto, Marcella ;
Massarotti, Alberto ;
Coluccia, Antonio ;
Brancale, Andrea .
CURRENT OPINION IN PHARMACOLOGY, 2016, 30 :116-130
[7]   Biochemical Basis of Vosevi, a New Treatment for Hepatitis C [J].
Besandre, Ronald ;
Liu, Hung-wen .
BIOCHEMISTRY, 2018, 57 (05) :479-480
[8]   Impact of Traditional Plants and their Secondary Metabolites in the Discovery of COVID-19 Treatment [J].
Bibi, Shabana ;
Sarfraz, Ayesha ;
Mustafa, Ghazala ;
Ahmad, Zeeshan ;
Zeb, Muhammad A. ;
Wang, Yuan-Bing ;
Khan, Tahir ;
Khan, Muhammad S. ;
Kamal, Mohammad A. ;
Yu, Hong .
CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (09) :1123-1143
[9]   High-throughput crystallography for lead discovery in drug design [J].
Blundell, TL ;
Jhoti, H ;
Abell, C .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (01) :45-54
[10]   NS5B polymerase inhibitors in phase II clinical trials for HCV infection [J].
Borgia, Guglielmo ;
Maraolo, Alberto Enrico ;
Nappa, Salvatore ;
Gentile, Ivan ;
Buonomo, Antonio Riccardo .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (03) :243-250